Corcept Therapeutics Inc (NASDAQ: CORT) has recently enjoyed extremely meaningful positive changes in investment behavior: the stock’s recent price rise disrupted its longer term downtrend, and its longer term price trend turned up.
Recent meaningful positive changes in fundamentals have benefitted Corcept Therapeutics Inc (NASDAQ: CORT): significant quarterly earnings acceleration occurred, and the consensus estimate for December, 2025 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of D. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
CORT is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Corcept Therapeutics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Corcept Therapeutics has a very low Appreciation Score of 13 but a slightly positive Power Rating of 64, resulting in the Negative Value Trend Rating.
Recent Price Action
Corcept Therapeutics Inc (NASDAQ: CORT) stock closed at $32.35 on 7/15/24 after a large increase of 2.7%. However, trading volume in this advance was unusually low at 60% of normal. The stock has risen 7.5% during the last week and has performed in line with the market over the last nine months.
Be the first to comment